Hyperimmunized egg product for treatment or prevention of coronavirus infection
In one aspect, the present disclosure is directed to a method for preventing or treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating coronavirus infection in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to the coronavirus. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from i) a spike (S) protein, an S1 subunit protein, an S2 subunit protein, a receptor binding domain (RBD), and an immunogenic fragment thereof; ii) a nucleocapsid (N) protein, and an immunogenic fragment thereof; iii) a human ACE2 receptor protein, and an immunogenic fragment thereof; and iv) a human coronavirus selected from the group consisting of SARS-CoV, MERS-CoV, SARS-CoV-2, HCoV-HKU1, HCoV-NL63, HCoV-OC43 and HCoV-229E. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.
1. A method of preparing a hyperimmunized egg product comprising:
a) hyperimmunizing an egg-producing animal with a composition comprising an antigen having the amino acid sequence of SEQ ID NO: 19 and
b) preparing a hyperimmunized egg product from one or more eggs produced by the animal by dehydrating, spray drying, or freeze drying of whole egg, yolk or a purified IgY fraction from the one or more eggs.
2. The method of claim 1 , wherein the hyperimmunized egg product is in a form of nanoparticles having a diameter less than 1000 nm.
3. The method of claim 1 , wherein the hyperimmunized egg product is in the form of microparticles having a diameter in a range of about 0.1 to 10 microns.
4. The method of claim 1 , wherein the hyperimmunized egg product is in the form of nanoparticles having a diameter in a range of about 10 to 100 nm.
5. The method of claim 1 , further comprising encapsulating the hyperimmunized egg product in an encapsulating material.
6. The method of claim 5 , wherein the encapsulating is performed by a process selected from among multi-walled microencapsulation, hot melt encapsulation, phase separation encapsulation, spontaneous emulsion, solvent evaporation microencapsulation, solvent removal microencapsulation, and coacervation.
7. The method of claim 1 , further comprising mixing the hyperimmunized egg product with an agent that improves flow properties.